Aspira Women’s Health and Cleveland Clinic have signed a Master Collaboration and License Agreement to advance AI-powered, non-invasive diagnostics for women’s health. The collaboration will focus on biomarker discovery and validation, advanced analytical model development, and clinical research initiatives – with a framework for future expansion across multiomic diagnostics.
Aspira currently offers OvaSuite, the only comprehensive portfolio of blood tests to aid in detecting ovarian cancer risk, serving the 1.2 million American women diagnosed with an adnexal mass each year. Its development pipeline includes expanding the ovarian cancer portfolio by combining microRNA and protein biomarkers with patient data, and building what the company describes as the first non-invasive test designed to identify endometriomas, one of the most common forms of severe endometriosis.
“We believe the integration of multiomic biomarkers with advanced AI-driven analytics represents a highly promising frontier in precision diagnostics,” said Dr. Kevin Elias, Lilli and Seth Harris Endowed Chair for Ovarian Cancer Research at Cleveland Clinic. “We have already demonstrated the potential of this approach to improve ovarian cancer diagnostics, and we believe it can be applied more broadly across women’s health.”
“This collaboration marks an important inflection point for Aspira as we continue executing against our strategy to build a category defining women’s health diagnostics platform,” said CEO Mike Buhle.
The initiative brings together Aspira’s AI-enabled multiomic platform with Cleveland Clinic’s translational research expertise and patient sample access.
